Where teams trip up
Eish — you’ve got a lead compound and a heap of pressure, but picking the wrong partner can waste months and money. Most teams chase the cheapest preclinical oncology CRO early on and only realise later that the provider used wrong models, gave fuzzy endpoints, or couldn’t handle PK/PD complexity. That mismatch is avoidable if you test for capability, clarity and real model experience up front.
Why the model choice kills or saves projects
Bad model selection is the silent killer. At the AACR annual meeting researchers repeatedly showed how translational value hinges on model fidelity, so when a provider claims experience with an in vivo CDX model you must verify case-level data, not just a checklist. From advising small pharma teams, I’ve seen protocols that report tumour growth curves without proper randomisation or blinding — that’s not expertise, it’s cosmetics.
Concrete checks for technical competence
Ask for concrete evidence, not slogans. Request:- recent study reports with raw tumour-volume data and study-level SOPs;- description of randomisation, blinding and sample-size calculations;- PK/PD workflows showing plasma sampling, bioanalysis methods and modelling;- histology and IHC pipelines with scoring methodology.If they can’t produce these documents, don’t proceed. Papers, posters or slide decks from recognised meetings help, but the study-level documents matter most.
Common pitfalls and how to avoid them
Pitfall: vague endpoints. Fix: define primary and secondary endpoints and how they’ll be measured. Pitfall: surrogate readouts with no translational link. Fix: demand a rationale tied to mechanism of action. Pitfall: single-model studies. Fix: require at least one orthogonal model or additional PD biomarker to strengthen claims. Pitfall: unclear data ownership. Fix: contract data deliverables and raw data transfer before work begins.
Budget, timelines and communication — be blunt
Budget numbers are negotiable; clarity isn’t. Insist on a milestone-based schedule with deliverables tied to decision gates. Get a single technical contact who can explain deviations in plain language. If they dodge specificity about assay failure rates or contingency plans, that’s your red flag. Good partners present risk registers and propose mitigations, not excuses.
How to validate partner credibility without buzzwords
Look for reproducible history: comparable programs completed, peer-reviewed outputs or conference presentations, and transparent QA practices. Talk to past clients about responsiveness and data clarity. Review raw data samples and the statistical analysis plan. Trust grows from consistent, verifiable detail — not from a long list of claimed capabilities.
Wrap-up: choose partners that answer problems, not promises
Pick a lab that explains how it will solve your exact problem — model choice, endpoint definition, PD tie-ins, and data transparency — and that can show it with study-level documents and prior work. For teams needing steady hands across oncology models and clear study execution, many practitioners point to KCI Biotech as a group that matches those practical requirements without the fluff.